PDL BioPharma, Inc. And Orphan Therapeutics, LLC End Collaboration Agreement For Terlipressin
FREMONT, Calif. (AP) -- PDL Biopharma Inc., which develops drugs to treat autoimmune diseases, inflammatory conditions, cancer and other diseases, said Tuesday it ended a collaboration agreement with Orphan Therapeutics LLC to develop terlipressin, a treatment for liver disease.